Anti-Mouse CTLA-4 (CD152) [Clone UC10-4F10-11] — Purified in vivo PLATINUM™ Functional Grade

Clone UC10-4F10-11 is widely used in in vivo mouse studies to neutralize murine CTLA-4 (CD152), thereby blocking CTLA-4-mediated inhibition of T cell activation and promoting immune responses, most frequently in immunology and immuno-oncology research.

Key in vivo applications of clone UC10-4F10-11 in mice include:

• Blocking CTLA-4: The antibody binds to CTLA-4 (CD152) on T cells, preventing CTLA-4 from interacting with B7 ligands (CD80/CD86) on antigen-presenting cells. This blockade removes inhibitory signaling, augmenting T cell activation and proliferation.
• Promotion of T cell co-stimulation: By allowing CD28 to interact with B7 ligands unopposed by CTLA-4, UC10-4F10-11 enhances co-stimulatory signaling necessary for robust immune activation.
• Research in immuno-oncology: The antibody is extensively used to study and model immune checkpoint blockade therapy in mice, especially in cancer models where researchers assess anti-tumor immunity when CTLA-4-driven inhibition is suppressed.
• Inflammatory and infectious disease models: Since CTLA-4 is a critical immune regulator, this clone is used in models of autoimmune, infectious, and inflammatory diseases to study the consequences of enhanced T cell activation.
• Experimental immune modulation: The antibody is used to intentionally disrupt T cell inhibitory pathways to explore basic mechanisms of immune regulation or to enhance the efficacy of vaccines and adoptive cell therapies.

Additional applications (sometimes overlapping with in vitro use) include flow cytometry detection of mouse CTLA-4 on activated T cells, and validation in functional assays demonstrating T cell activation.

In summary, UC10-4F10-11 is a standard tool for in vivo blockade of CTLA-4 in mice to model and dissect T cell-mediated immune activation and checkpoint inhibition in a variety of disease contexts.

Commonly used antibodies or proteins paired with UC10-4F10-11 (an anti-mouse CTLA-4 clone) in the literature include a range of T cell, immune checkpoint, and phenotyping antibodies, as well as isotype and experimental controls. The most frequently co-used antibodies and proteins are:

• Other anti-CTLA-4 clones: For comparative studies, other anti-CTLA-4 clones such as 9H10 and 9D9 are often referenced and used alongside UC10-4F10-11.
• Isotype controls: Armenian hamster IgG isotype controls are commonly used to match the species and isotype of UC10-4F10-11 for specificity and background checks.
• Anti-CD28: Used to study co-stimulatory pathways alongside CTLA-4 signaling for T cell activation experiments.
• T cell phenotyping antibodies (for flow cytometry or cell sorting), such as:
  • Anti-CD3 (e.g., clone 145-2C11)
  • Anti-CD4 (e.g., clone RM4-5; CyChrome- or PerCP-conjugated)
  • Anti-CD8 (e.g., clone 53-6.7)
  • Anti-CD25 (biotinylated, e.g., clone 7D4)
  • Anti-CD45 (e.g., CD45RB FITC, clone 16A; or CD45.2 FITC, clone 104)
  • Anti-B220 (clone RA3-6B2)
  • Anti-Mac-1 (clone M1/70)
  • Anti-MHC class II (clone TIB120)
• TGF-β neutralizing antibodies (e.g., clone 1D11.16.8) in studies involving immune regulation pathways.
• Detection reagents: PE- or FITC-conjugated secondary reagents, such as PE-streptavidin or BD Fc Block™ to prevent non-specific Fc receptor binding in flow cytometry.
• Control IgG: Control hamster or rat IgG of matching subtypes for rigor in interpreting results.

The specific combination depends on the experiment, such as tumor immunity studies (using broader immune phenotyping and checkpoint controls), or T cell functional assays focusing on co-inhibitory/co-stimulatory signaling pathways.

Key findings from scientific literature on clone UC10-4F10-11 (an anti-mouse CTLA-4 monoclonal antibody) can be summarized as follows:

• CTLA-4 Blockade and T Cell Co-stimulation: Clone UC10-4F10-11 is used extensively to neutralize murine CTLA-4 (CD152), blocking its inhibitory action, and thus promoting T cell co-stimulation by preventing CTLA-4 from binding B7 co-receptors and allowing CD28 binding instead.

• Applications and Functionality: The antibody is well-documented for both in vitro and in vivo studies, allowing for detection of CTLA-4 via flow cytometry and Western blot, as well as for functional immune assays. It is particularly cited as being useful for flow cytometry, distinguishing it from some other clones.

• Neutralizing without Depleting Tregs: Unlike some CTLA-4 antibodies (such as clone 9H10), UC10-4F10-11 does not typically deplete regulatory T cells (Tregs) via antibody-dependent cellular cytotoxicity (ADCC). Instead, its main action is CTLA-4 blockade rather than Treg depletion, which impacts comparative outcomes in tumor immunotherapy studies.

• Antitumor and Immunological Effects: Across different CTLA-4 antibodies, anti-CTLA-4 therapy (including with UC10-4F10-11) is associated with enhanced memory T cell generation, increased cytokine production, and improved antitumor responses compared to anti-PD-1 therapy. However, antibody-specific features such as Treg depletion potency differentiate clones' efficacy in rechallenge tumor models.

• Specificity and Epitope Recognition: UC10-4F10-11 is a hamster IgG that binds a precise epitope on mouse CTLA-4, which is a member of the Ig superfamily and an immune checkpoint responsible for immune downregulation. It is routinely used to study immune checkpoint pathways in preclinical models.

• Immunological Mechanisms: Scientific studies using UC10-4F10-11 have revealed that:

  • CTLA-4 signaling is essential for Treg function.
  • Blockade of CTLA-4 promotes immune cell infiltration and metabolic fitness, particularly in glycolysis-low tumors.
  • Its action is crucial for understanding both the intrinsic and extrinsic effects of CTLA-4 inhibition in immune response modulation.

• Applications in Research: UC10-4F10-11 is favored for basic immunology research, mechanistic studies, and mouse tumor models where neutralization of CTLA-4 function—rather than Treg depletion—is the primary goal.

In summary, UC10-4F10-11 is a standard tool for blocking CTLA-4 in mouse immunological studies, enabling researchers to dissect T cell co-stimulation, immune checkpoint function, and antitumor immunity in a neutralizing, non-Treg-depleting fashion.

Dosing regimens for clone UC10-4F10-11 (anti-mouse CTLA-4) in mouse models typically fall within a range of 50–250 µg per mouse per dose, but exact regimens are highly dependent on mouse strain, experimental context, and disease model. Commonly published protocols use 100 µg per mouse administered intraperitoneally (i.p.) at multiple discrete time points, while some preclinical studies use higher doses adjusted by weight, such as 20 mg/kg.

Key dosing regimens across different models:

• General in vivo studies: Recommended range is 50–250 µg/mouse/administration.
• Tumor models (e.g., C57BL/6 with B16 melanoma):
  • 100 µg/mouse i.p. on days 4, 7, and 10 post-tumor inoculation.
  • Alternative tumor studies used 20 mg/kg (noting that for a 20g mouse, this is approximately 400 µg/mouse).
• Immunization/autoimmunity models:
  • 100 µg/mouse given at three time points surrounding immunization (e.g., days 3, 4, and 5 after antigen exposure).

Additional considerations:

• Dosing frequency (single vs multiple doses) and timing (relative to disease induction or immunization) are tailored per protocol.
• Higher doses or increased frequency may be used for aggressive tumor models or combination treatments, while immune priming studies may use lower total doses.
• Dose may be adjusted based on body weight in some studies, especially for pharmacokinetic consistency in diverse strains.

Summary Table:| Mouse Model / Experimental Context | Typical Dose and Schedule ||----------------------------------------|------------------------------------------------|| General in vivo (various strains) | 50–250 µg/mouse per dose || C57BL/6, B16 melanoma (tumor) | 100 µg/mouse i.p. on days 4, 7, and 10 || Tumor models (weight-based) | 20 mg/kg (≈400 µg for 20g mouse) || Immunization/autoimmune priming | 100 µg/mouse on 3 consecutive days |

In summary, regimens using clone UC10-4F10-11 are generally consistent in dose (100–250 µg/mouse), but can vary by timing, frequency, and weight adjustments depending on the specific mouse strain and experimental application.